<code id='1E1B5F7DC1'></code><style id='1E1B5F7DC1'></style>
    • <acronym id='1E1B5F7DC1'></acronym>
      <center id='1E1B5F7DC1'><center id='1E1B5F7DC1'><tfoot id='1E1B5F7DC1'></tfoot></center><abbr id='1E1B5F7DC1'><dir id='1E1B5F7DC1'><tfoot id='1E1B5F7DC1'></tfoot><noframes id='1E1B5F7DC1'>

    • <optgroup id='1E1B5F7DC1'><strike id='1E1B5F7DC1'><sup id='1E1B5F7DC1'></sup></strike><code id='1E1B5F7DC1'></code></optgroup>
        1. <b id='1E1B5F7DC1'><label id='1E1B5F7DC1'><select id='1E1B5F7DC1'><dt id='1E1B5F7DC1'><span id='1E1B5F7DC1'></span></dt></select></label></b><u id='1E1B5F7DC1'></u>
          <i id='1E1B5F7DC1'><strike id='1E1B5F7DC1'><tt id='1E1B5F7DC1'><pre id='1E1B5F7DC1'></pre></tt></strike></i>

          
          WSS
          Adam's take main illustration
          Molly Ferguson/STAT

          Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

          Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

          advertisement

          Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          hotspot